This prospective trial evaluated first-line osimertinib combined with platinum and etoposide in patients with EGFR-mutant lung adenocarcinoma harboring concurrent TP53 and RB1 alterations, who are at high risk for histological transformation. Despite incorporating SCLC-directed chemotherapy upfront, nearly half of the patients (5 of 11) experienced SCLC transformation, yielding a median progression-free survival of 11 months and a median overall survival of 33 months. Genomic and single-cell transcriptomic analyses revealed pronounced phenotypic plasticity towards SCLC, mesenchymal, and squamous lineages. These lineage shifts were driven by progressive disruption of the RB pathway and chromatin remodeling, which were further amplified under the selective pressure of osimertinib treatment.
This large-scale pan-cancer study of nearly 69,000 tumor-normal pairs profiled by MSK-IMPACT characterizes the biological and clinical implications of SMARCA4 alterations across functional mutation classes and allelic configurations. SMARCA4 alterations were most frequently observed in thymic epithelial tumors (10.7%), non-small cell lung cancer (7.1%), bladder cancer (5.6%), and cervical cancer (5%). Distinct profiles of genomic complexity, co-mutations, and mutational signatures were associated with specific allelic states (monoallelic vs. biallelic) and mutation classes (class 1 vs. class 2). Preliminary data from a phase I trial of the BRM degrader PRT3789 revealed clinical benefit, including one complete response, among patients harboring monoallelic class 2 SMARCA4 alterations with preserved BRG1 expression.
This study evaluates HPV-DeepSeek, a whole-genome sequencing assay analyzing circulating tumor HPV DNA (ctHPVDNA), coupled with the novel computational classifier HPV-SIGNAL across 235 HPV-positive cancers representing 9 anatomic sites. The assay demonstrated 99% diagnostic sensitivity and specificity while identifying four distinct viral physical states in plasma: episomal-only, episomal-rearranged, integrated-mixed, and integrated-clonal. Patients with circulating integrated viral states had significantly worse progression-free and overall survival compared to those with episomal forms. Consequently, this non-invasive approach establishes plasma-based HPV physical state classification as a potent prognostic tool at initial cancer diagnosis.
The innovaTV 204 study evaluated tisotumab vedotin (TV), a tissue factor (TF)-targeting antibody-drug conjugate, in patients with recurrent or metastatic cervical cancer. Although TF expression is required for TV binding, clinical responses were found to be independent of TF levels. This analysis revealed that higher expression of gene signatures linked to natural killer (NK) cells and myeloid cells was associated with improved clinical outcomes. In vitro studies confirmed that TV induces tumor cell death through myeloid-mediated ADCP and NK-mediated ADCC mechanisms, irrespective of TF levels. These findings suggest a multimodal mechanism of action for TV, involving both direct cytotoxicity and immune effector-mediated effects.
The TRIDENT study is a post-hoc analysis of the phase III POSEIDON trial, which evaluated the addition of tremelimumab to durvalumab and chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC). This analysis utilized machine learning models integrating clinical, genomic, and radiomic data to identify patients who would derive greater overall survival (OS) benefit from the addition of tremelimumab. Results showed that the top-ranked 50% of patients with nonsquamous tumors, as identified by the model, achieved a hazard ratio of 0.56 for OS. Factors such as KRAS and STK11 mutations, along with wild-type EGFR, FGFR3, and CDKN2A, were strongly associated with higher OS benefit.
This study investigates resistance mechanisms to KRAS G12D inhibitors, such as HRS-4642, in pancreatic ductal adenocarcinoma (PDAC). Researchers identified the reactivation of the unfolded protein response (UPR) via the MEK/ERK pathway as a key mechanism of acquired resistance, observed in vitro, in vivo, and in patients. To overcome this resistance, a combination therapy with nimotuzumab was tested, demonstrating strong synergy and resistance reversal. Nimotuzumab sustained the suppression of the MEK/ERK/UPR axis while exacerbating endoplasmic reticulum stress, leading to profound cellular damage. These findings suggest a promising combined strategy for PDAC patients harboring KRAS G12D mutations.
This study investigated the concordance of circulating tumor human papillomavirus DNA (ctHPVDNA) with tissue-based HPV testing for diagnosing HPV-associated oropharyngeal squamous cell carcinoma (HPV+OPSCC). Researchers analyzed 236 patients, comparing ctHPVDNA (NavDx assay) results with p16 immunohistochemistry and ISH. ctHPVDNA demonstrated 100% specificity and positive predictive value, suggesting a positive result is highly reliable. However, its sensitivity of 85% and negative predictive value of 17% indicate that a negative result still necessitates confirmation with tissue-based tests.
This study benchmarks whole-genome sequencing (WGS) performance between Element AVITI and Illumina NovaSeq X Plus platforms using four human tumor cell lines. AVITI demonstrated lower duplication rates and higher base qualities, leading to improved mapping confidence and fewer spurious variant candidates. While both platforms were highly comparable for variant calling, AVITI offered a minor improvement for INDELs at lower coverages. Contextual differences were observed, with AVITI performing better in high-GC regions but worse in GC homopolymers, and showing sensitivity to G-quadruplex motifs. Overall, despite these specific differences, both platforms delivered highly comparable results for variant analysis.